Inscripta, Inc., a Boulder, Colo.-based provider of an automated benchtop instrument for genome-scale engineering, raised $125m in Series D financing.
The round, which brought the total amount raised to date to $259.5m, was led by Paladin Capital Group with participation from existing investors (Venrock, Foresite, Mérieux Développement, NanoDimension, and MLS Capital) and new investors JS Capital Management LLC and Oak HC/FT.
The company intends to use the funds ti accelerate applications expansion and commercialization of its Onyx™ Digital Genome Engineering platform.
Led by Kevin Ness, PhD, CEO, Inscripta is developing a benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables trackable editing of single cells at scale.
The platform gives scientists in genome discovery, healthcare, bio-industrial materials development and manufacturing, and sustainability the chance to design, engineer, evaluate, and track results of genome engineering experiments in their own labs.
The company also has offices in Pleasanton, Calif., and San Diego.